Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

Their solution, VetEvince, went beyond simple automation or AI chat assistants. It promised to deliver insights anchored in ...

Acclinate released its 2025 annual NOWINCLUDED impact report, highlighting how its community-first engagement model reached 20 million people and translated trust into measurable health actions. This ...

Pioneering biostatistician and infectious disease expert Dr. Elizabeth Halloran recently transitioned to emerita after a ...

The suit alleges that social media companies knew about risks to children and teens but pushed ahead with marketing anyway.

Lawsuits in California federal and state court are unearthing documents embarrassing to tech companies — and may be a tipping ...

Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −Highlights Phase 2 data for ATH434 in Multiple System ...

Jay Bhattacharya, the N.I.H. director, says authorities broke the public’s trust in the Covid era. Now it’s up to outsiders ...

JAMA named nine of the most influential studies of 2025, including three in neurology. Medscape interviews the researchers to explore the findings and what they could mean for brain health.

FDA approvals, trial progress and early commercial momentum put several ASX healthcare companies in a strong position heading ...

Union Finance Minister Nirmala Sitharaman will on February 1 present the Union Budget 2026-27 in which she will also highlight the budget for the education sector in the new financial year. In last ...

Optimizing drug delivery to the lymphatic system is essential for effective cancer treatment, as lymph node (LN) metastasis ...